Progestin Therapy in Endometriosis

Altay Gezer; Engin Oral

doi:10.2217/whe.15.42

Progestin Therapy in Endometriosis

Altay Gezer, Engin Oral

Women's health (London, England) · 2015 · vol. 11(5) , pp. 643–652 · doi:10.2217/whe.15.42 · PMID:26389558 · W2204545205

review OA: gold CC0 ⤵ 38 in-corpus citations

📄 Open PDF View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Progestins, used for over 50 years in various forms, effectively reduce endometriosis pain symptoms in approximately 90% of patients, though no superiority over other treatments has been proven.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Progestins are synthetic compounds that mimic the effects of progesteron. For over 50 years, oral progestins have been demonstrated to be effective in the treatment of endometriosis. They were reported to reduce or eliminate pain symptoms in approximately 90% of the patients. Progestins are available in many forms, including oral preparations, injections, subdermal implants and intrauterine systems. Continuous progestin use is an effective therapy for the treatment of painful symptoms associated with endometriosis but there had been no evidence of progestin use being superior to other types of treatment in endometriosis-related pain symptoms.

My notes (saved in your browser only)

Condition tags

mesh:D004715mesh:D017699endometriosis

MeSH descriptors

Endometriosis Pelvic Pain Progestins Drug Implants Endometriosis Endometriosis Endometrium Endometrium Female Humans Intrauterine Devices, Medicated Pelvic Pain Pelvic Pain Progestins

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (47)

Cited by (38)

Source provenance

europepmc: last seen: 2026-06-04T01:30:01.192114+00:00
openalex: last seen: 2026-06-04T00:00:01.174412+00:00
pubmed: last seen: 2026-05-13T22:17:39.907309+00:00

License: CC0 · commercial use OK

[1] A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis via openalex

[2] A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis via openalex

[3] A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study via openalex

[4] Aromatase and other steroidogenic genes in endometriosis: translational aspects via openalex

[5] Changes in quality of life after hormonal treatment of endometriosis via openalex

[6] Clinical Management of Endometriosis via openalex

[7] Clinical Management of Endometriosis via openalex

[8] Combined hysteroscopic and laparoscopic findings in patients with chronic pelvic pain via openalex

[9] Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis via openalex

[10] Deficient 17β-Hydroxysteroid Dehydrogenase Type 2 Expression in Endometriosis: Failure to Metabolize 17β-Estradiol<sup>1</sup> via openalex

[11] Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis via openalex

[12] Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis via openalex

[13] Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells via openalex

[14] Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex

[15] Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex

[16] Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study via openalex

[17] Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model via openalex

[18] Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study via openalex

[19] Endometrial nerve fibers in women with endometriosis, adenomyosis, and uterine fibroids via openalex

[20] Endometriosis: Science and Practice via openalex

[21] Endometriosis treated with lynestrenol. via openalex

[22] Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial via openalex

[23] Medical Therapies: Progestins via openalex

[24] Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis via openalex

[25] Post-operative oral contraceptive use reduces the risk of ovarian endometrioma recurrence after laparoscopic excision via openalex

[26] Prevalence of endometriosis in asymptomatic women. via openalex

[27] Progesterone and progestational compounds attenuate tumor necrosis factor alpha–induced interleukin-8 production via nuclear factor kappaB inactivation in endometriotic stromal cells via openalex

[28] Progestins for symptomatic endometriosis: a critical analysis of the evidence via openalex

[29] Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis via openalex

[30] Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex

[31] Steroidal regulation of endometriosis tissue: lack of induction of 17β-hydroxysteroid dehydrogenase activity by progesterone, medroxyprogesterone acetate, or danazol via openalex

[32] Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain via openalex

[33] Subcutaneous versus Intramuscular Depot Methoxyprogesterone Acetate: A Comparative Review via openalex

[34] The current place of progestins in the treatment of endometriosis via openalex

[35] The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up via openalex

[36] The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis via openalex

[37] The place of dydrogesterone in the treatment of endometriosis and adenomyosis via openalex

[38] The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis via openalex

[39] Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate via openalex

[40] Visible and non-visible endometriosis at laparoscopy in fertile and infertile women and in patients with chronic pelvic pain: a prospective study via openalex

[41] W4285719527 via openalex

[42] W2123134517 via openalex

[43] W2101417341 via openalex

[44] W2157853773 via openalex

[45] W4211081176 via openalex

[46] W2045458073 via openalex

[47] W1978085719 via openalex